Biotest AG
Biotest AG: Biotest significantly exceeds EBIT guidance 2022

Ad hoc NOTICE

Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)

 

 Biotest significantly exceeds EBIT guidance 2022

 

Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in the previous year.

EBIT improved strongly in the 2022 financial year to € – 16.6 million after € – 47.1 million in the previous year. This means that the EBIT achieved is significantly above the forecast range of € – 20 to – 25 million, taking into account accelerated R&D activities. The risks still seen in March 2022 in connection with the war in Ukraine did not materialise to the extent expected. In November 2022, a possible increase in losses to a range of € – 40 million to € – 60 million was excluded.

The Biotest Group’s core business (adjusted EBIT) is profitable at € 60.7 million (previous year: € 29.4 million) and the positive result is in the upper range of the forecast range of
€ 40 to 70 million.

The aforementioned figures of the Biotest Group were determined according to IFRS.

Due to the lack of a balance sheet profit in the individual financial statements of Biotest AG in accordance with the German Commercial Code (HGB) in the financial year 2022, which is the assessment basis for the ability to distribute profits, the Management Board and the Supervisory Board will therefore not be able to submit a proposal for the appropriation of profits for preference and ordinary shareholders to this year’s Annual General Meeting. There are no reserves available that can be used for dividend distribution. Therefore, no dividend will be distributed.

Biotest will publish the final figures for the 2022 financial year and the annual report on
23 March 2023.

 

Biotest Aktiengesellschaft
The Board of Management
 

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich

www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,200 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

 

IR contact

Dr Monika Buttkereit
Phone: +49-6103-801-4406
E-mail: ir@biotest.com

 

PR contact

Dirk Neumüller
Phone: +49-6103-801-269
E-mail: pr@biotest.com

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

 

Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
Michael.ramroth@biotest.com